HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Veterinary Medicine / Faculty of Veterinary Medicine >
Peer-reviewed Journal Articles, etc >

Serial measurement of pancreatic lipase immunoreactivity concentration in dogs with immune-mediated disease treated with prednisolone

Files in This Item:
JSAP_58(6)_342-347_for_HUSCAP.pdf130.78 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/70667

Title: Serial measurement of pancreatic lipase immunoreactivity concentration in dogs with immune-mediated disease treated with prednisolone
Authors: Ohta, H. Browse this author →KAKEN DB
Morita, T. Browse this author
Yokoyama, N. Browse this author
Osuga, T. Browse this author
Sasaki, N. Browse this author →KAKEN DB
Morishita, K. Browse this author →KAKEN DB
Nakamura, K. Browse this author →KAKEN DB
Takiguchi, M. Browse this author →KAKEN DB
Issue Date: Jun-2017
Publisher: John Wiley & Sons
Journal Title: Journal of small animal practice
Volume: 58
Issue: 6
Start Page: 342
End Page: 347
Publisher DOI: 10.1111/jsap.12652
PMID: 28247954
Abstract: Objectives: In this pilot study, serum canine pancreatic lipase immunoreactivity was measured repeatedly in dogs with various immune-mediated diseases that were treated with immunosuppressive doses of prednisolone. Methods: Ten client-owned dogs with newly diagnosed immune-mediated disease that had normal canine pancreatic lipase immunoreactivity concentrations (200 mu g/l) were treated with 2 to 2.2 mg/kg prednisolone orally once daily as the initial treatment. Serum samples were obtained from each of the dogs prior to treatment and at 1- to 4-week intervals during immunosuppressive treatment. The highest canine pancreatic lipase immunoreactivity concentration detected during immunosuppressive treatment was defined as the peak canine pancreatic lipase immunoreactivity. Results: Peak canine pancreatic lipase immunoreactivity concentrations were classified as normal in two dogs, questionable (201 to 399 mu g/l) in three dogs, and abnormal (≥400 mu g/l) in five dogs. Peak canine pancreatic lipase immunoreactivity concentrations were significantly higher than baseline canine pancreatic lipase immunoreactivity concentrations but there was no evidence of clinical pancreatitis. Clinical Significance: It remains unclear whether the five of 10 dogs with elevated canine pancreatic lipase immunoreactivity during prednisone treatment had subclinical pancreatitis or whether the abnormal results were a consequence of prednisolone administration.
Rights: This is the peer reviewed version of the following article: H. Ohta, T. Morita, N. Yokoyama, T. Osuga, N. Sasaki, K. Morishita, K. Nakamura, M. Takiguchi, Serial measurement of pancreatic lipase immunoreactivity concentration in dogs with immune-mediated disease treated with prednisolone, Journal of Small Animal Practice, Vol. 58, Issue 6, June 2017, which has been published in final form at https://doi.org/10.1111/jsap.12652. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
Type: article (author version)
URI: http://hdl.handle.net/2115/70667
Appears in Collections:獣医学院・獣医学研究院 (Graduate School of Veterinary Medicine / Faculty of Veterinary Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 大田 寛

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University